Overall, preclinical experiments have demonstrated that VEGF signaling plays an important role in anti-EGFR therapy resistance and the combination of VEGFR and EGFR inhibitors has been associated with improved anti-tumor activity in xenografts [113]. Here, EGFR is linked to neoplasm.